ADAGENE INC. - ADS EACH REPRESENTING 1.25 ORDINAR

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

12 Aug 2025 13:05:01 By Nasdaq GlobeNewswire

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

15 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

08 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Adagene announces up to $25 million strategic investment from Sanofi

01 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Adagene to Present at Jefferies Global Healthcare Conference 2025

27 May 2025 04:30:00 By Nasdaq GlobeNewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

22 May 2025 14:05:00 By Nasdaq GlobeNewswire

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

28 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 07:05:00 By Nasdaq GlobeNewswire

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

07 Apr 2025 05:00:01 By Nasdaq GlobeNewswire

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

24 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

13 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Adagene to Present at Leerink’s Global Healthcare Conference 2025

06 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

27 Feb 2025 05:00:01 By Nasdaq GlobeNewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

27 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

21 Jan 2025 14:00:00 By Nasdaq GlobeNewswire

Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025

14 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

07 Nov 2024 07:01:00 By Nasdaq GlobeNewswire

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

09 Oct 2024 03:00:00 By Nasdaq GlobeNewswire

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

16 Sep 2024 00:01:00 By Nasdaq GlobeNewswire

Adagene to Participate in Investor Conferences in September

29 Aug 2024 04:00:00 By Nasdaq GlobeNewswire